Company Profile

Avedro Inc (AKA: ThermalVision Inc)
Profile last edited on: 12/1/2023      CAGE: 59N76      UEI: XVMEKBSUMGZ7

Business Identifier: Ophthalmic surgery and medical devices: corneal cross-linking and refractive correction
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

230 Third Avenue
Waltham, MA 02451
   (781) 768-3400
Location: Single
Congr. District: 05
County: Middlesex

Public Profile

Formerly doing business as ThermalVision, Avedro, Inc., is a medical device company advancing the science and technology of corneal cross-linking and refractive correction.. The firm offers a non-invasive refractive correction procedure that reshapes the cornea. The company also develops systems for performing corneal cross-linking for the treatment of keratoconus and post-Lasik ectasia; and solutions for the correction of myopia and other refractive disorders. In addition, it offers accessories, such as targeting stages and applicators, as well as bioinsulators for the dielectrically controlled transmission of the microwave energy. Further, the company involves in developing the science of thermo-biomechanics for therapeutic medical applications. Avedro recently completed its US?based, multi-centered, Phase III studies of corneal cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery. Outside the United States, Avedro has commercialized both VibeX and its KXL System for performing Lasik Xtra and accelerated cross-linking. Additionally, Avedro is developing the science of Thermo-biomechanics for therapeutic medical applications. The Keraflex® refractive correction procedure is the first technology developed from the Thermo-biomechanics platform and is a non-invasive, incision-less ophthalmic procedure for flattening the cornea without the removal of tissue. Keraflex offers the unique ability to induce refractive change without weakening the cornea’s biomechanical integrity, as happens with Lasik and other refractive correction procedures. Keraflex is commercially available outside of the United States.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2007 2 NIH $868,761
Project Title: Commercialization of microwave thermokeratoplasty

Key People / Management

  David Muller -- Founder, President and CEO

  Steve Blinn -- Chief Commercial Officer

  Marc D Friedman -- Chief Scientific Officer

  Ronald Scharf -- Chief Technology Officer

  Stuart B Trembly -- Chief Scientific Officer